Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7338135

NN=Cc1ccc2cc(C(=O)Nc3ccc(N)cc3)ccc2c1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 4/20 0.48
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
PKM P14618 1/20 0.46
APEX1 P27695 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PLAU P00749 6/20 0.44
PLG P00747 3/20 0.43
F2 P00734 2/20 0.43
KLKB1 P03952 2/20 0.43
PRSS1 P07477 2/20 0.43
PLAT P00750 2/20 0.43
KLK1 P06870 1/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
DEGS1 O15121 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7338119 1.00 PTGS1 (0.48) PTGS1MEN1LMNAPOLBPKM
Trifluoroacetic Acid SCHEMBL7344126 0.88 PLAU (0.58) KMT2APLAUPLGF2KLKB1
Trifluoroacetic Acid SCHEMBL7344120 0.88 PLAU (0.58) KMT2APLAUPLGF2KLKB1
Trifluoroacetic Acid SCHEMBL7344358 0.83 MEN1 (0.50) MEN1POLBKMT2APLAU
Trifluoroacetic Acid SCHEMBL7344371 0.83 MEN1 (0.50) MEN1POLBKMT2APLAU
SCHEMBL7340329 0.82 PLAU (0.63) MEN1KMT2APLAUPLGF2
Trifluoroacetic Acid SCHEMBL7335899 0.82 PLAU (0.49) MEN1KMT2ATDP1PLAUPLG
SCHEMBL7336457 0.81 NPC1 (0.53) MEN1POLBKMT2ATDP1PLAU
Trifluoroacetic Acid SCHEMBL7338129 0.80 PLAU (0.67) PTGS1MEN1LMNAPOLBPKM
Trifluoroacetic Acid SCHEMBL7335043 0.80 F2 (0.38) MEN1LMNAPKMKMT2APLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PTGS1 198/4885MEN1 1137/4885LMNA 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.